JP7479381B2 - 治療または予防に使用するためのディフェンシン断片 - Google Patents
治療または予防に使用するためのディフェンシン断片 Download PDFInfo
- Publication number
- JP7479381B2 JP7479381B2 JP2021539592A JP2021539592A JP7479381B2 JP 7479381 B2 JP7479381 B2 JP 7479381B2 JP 2021539592 A JP2021539592 A JP 2021539592A JP 2021539592 A JP2021539592 A JP 2021539592A JP 7479381 B2 JP7479381 B2 JP 7479381B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- diseases
- peptides
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012634 fragment Substances 0.000 title description 71
- 102000000541 Defensins Human genes 0.000 title description 13
- 108010002069 Defensins Proteins 0.000 title description 13
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 238000011321 prophylaxis Methods 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 186
- 230000000844 anti-bacterial effect Effects 0.000 claims description 105
- 238000011282 treatment Methods 0.000 claims description 29
- 244000005700 microbiome Species 0.000 claims description 27
- 230000004048 modification Effects 0.000 claims description 22
- 238000012986 modification Methods 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 150000008575 L-amino acids Chemical class 0.000 claims description 11
- -1 acetyl- Chemical group 0.000 claims description 10
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 210000001508 eye Anatomy 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 7
- 241000222122 Candida albicans Species 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 206010046914 Vaginal infection Diseases 0.000 claims description 6
- 201000008100 Vaginitis Diseases 0.000 claims description 6
- 238000011191 terminal modification Methods 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000001408 amides Chemical group 0.000 claims description 5
- 210000005069 ears Anatomy 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 3
- 206010007134 Candida infections Diseases 0.000 claims description 3
- 206010007247 Carbuncle Diseases 0.000 claims description 3
- 206010007882 Cellulitis Diseases 0.000 claims description 3
- 241001608562 Chalazion Species 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 206010011844 Dacryocystitis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 206010021531 Impetigo Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000010315 Mastoiditis Diseases 0.000 claims description 3
- 208000003926 Myelitis Diseases 0.000 claims description 3
- 206010051606 Necrotising colitis Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 206010057182 Periorbital cellulitis Diseases 0.000 claims description 3
- 208000000528 Pilonidal Sinus Diseases 0.000 claims description 3
- 206010035043 Pilonidal cyst Diseases 0.000 claims description 3
- 208000001280 Prediabetic State Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 3
- 208000002474 Tinea Diseases 0.000 claims description 3
- 241000130764 Tinea Species 0.000 claims description 3
- 208000007074 Trichomonas Vaginitis Diseases 0.000 claims description 3
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 208000010217 blepharitis Diseases 0.000 claims description 3
- 201000003984 candidiasis Diseases 0.000 claims description 3
- 208000002925 dental caries Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010014801 endophthalmitis Diseases 0.000 claims description 3
- 208000008025 hordeolum Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 201000004614 iritis Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 208000008588 molluscum contagiosum Diseases 0.000 claims description 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 206010033072 otitis externa Diseases 0.000 claims description 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 201000004700 rosacea Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 claims description 3
- 201000004647 tinea pedis Diseases 0.000 claims description 3
- 201000000200 vestibular neuronitis Diseases 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- 208000025157 Oral disease Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000025307 bipolar depression Diseases 0.000 claims description 2
- 208000032625 disorder of ear Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 125000005313 fatty acid group Chemical group 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 208000030194 mouth disease Diseases 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 208000013464 vaginal disease Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 101001041589 Homo sapiens Defensin-5 Proteins 0.000 description 136
- 102100021420 Defensin-5 Human genes 0.000 description 132
- 102000004196 processed proteins & peptides Human genes 0.000 description 73
- 101000929203 Homo sapiens Neutrophil defensin 4 Proteins 0.000 description 58
- 241000894006 Bacteria Species 0.000 description 57
- 102100036348 Neutrophil defensin 4 Human genes 0.000 description 57
- 238000002474 experimental method Methods 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 36
- 230000000694 effects Effects 0.000 description 36
- 102100029790 Defensin-6 Human genes 0.000 description 34
- 101000865479 Homo sapiens Defensin-6 Proteins 0.000 description 34
- 239000000203 mixture Substances 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 21
- 230000002183 duodenal effect Effects 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 210000002421 cell wall Anatomy 0.000 description 20
- 239000000539 dimer Substances 0.000 description 19
- 241001013691 Escherichia coli BW25113 Species 0.000 description 18
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 17
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 230000029087 digestion Effects 0.000 description 15
- 210000003134 paneth cell Anatomy 0.000 description 15
- 244000052616 bacterial pathogen Species 0.000 description 14
- 230000002949 hemolytic effect Effects 0.000 description 14
- 230000000813 microbial effect Effects 0.000 description 14
- 239000012530 fluid Substances 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 241000736262 Microbiota Species 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 12
- 239000004365 Protease Substances 0.000 description 12
- 102000018568 alpha-Defensin Human genes 0.000 description 12
- 108050007802 alpha-defensin Proteins 0.000 description 12
- 244000005709 gut microbiome Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 150000008574 D-amino acids Chemical class 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- 108090000631 Trypsin Proteins 0.000 description 10
- 102000004142 Trypsin Human genes 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000002797 proteolythic effect Effects 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- 239000001974 tryptic soy broth Substances 0.000 description 10
- 108010050327 trypticase-soy broth Proteins 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 9
- 241000192125 Firmicutes Species 0.000 description 8
- 108010033276 Peptide Fragments Proteins 0.000 description 8
- 102000007079 Peptide Fragments Human genes 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 239000012064 sodium phosphate buffer Substances 0.000 description 7
- 241000194031 Enterococcus faecium Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 6
- 108010013639 Peptidoglycan Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003968 anodic stripping voltammetry Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000010534 mechanism of action Effects 0.000 description 6
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 239000004475 Arginine Chemical group 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000588626 Acinetobacter baumannii Species 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000702462 Akkermansia muciniphila Species 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002376 chymotrypsin Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 206010012742 Diarrhoea infectious Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 231100000416 LDH assay Toxicity 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000095588 Ruminococcaceae Species 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108050002883 beta-defensin Proteins 0.000 description 2
- 102000012265 beta-defensin Human genes 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 238000002575 gastroscopy Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 208000010603 vasculitis due to ADA2 deficiency Diseases 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101710193393 Alpha-defensin 5 Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241001430149 Clostridiaceae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000164287 Enterococcus faecalis ATCC 19433 Species 0.000 description 1
- 206010058838 Enterocolitis infectious Diseases 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 1
- 101000830386 Homo sapiens Neutrophil defensin 3 Proteins 0.000 description 1
- 241000339806 Hydrogenoanaerobacterium Species 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000616258 Intestinimonas Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010061302 Myringitis Diseases 0.000 description 1
- 208000033212 Myringitis bullous Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100029494 Neutrophil defensin 1 Human genes 0.000 description 1
- 101800000287 Neutrophil defensin 2 Proteins 0.000 description 1
- 102100024761 Neutrophil defensin 3 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001267951 Parasutterella Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000256215 Spongomorpha aeruginosa Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010058042 Wound abscess Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- HQMRIBYCTLBDAK-UHFFFAOYSA-M bis(2-methylpropyl)alumanylium;chloride Chemical compound CC(C)C[Al](Cl)CC(C)C HQMRIBYCTLBDAK-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000010888 cage effect Methods 0.000 description 1
- 230000003047 cage effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007540 host microbe interaction Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 102000018475 human neutrophil peptide 2 Human genes 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000001257 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000027139 infectious colitis Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000004237 myringitis bullosa hemorrhagica Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- GRZXCHIIZXMEPJ-HTLKCAKFSA-N neutrophil peptide-2 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@@H](N)CSSC[C@H](NC2=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 GRZXCHIIZXMEPJ-HTLKCAKFSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- KRJOFJHOZZPBKI-KSWODRSDSA-N α-defensin-1 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CSSC[C@H](NC2=O)C(O)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 KRJOFJHOZZPBKI-KSWODRSDSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
配列HD-51-9ATCYCRTGR(配列番号1)または
配列番号1のリバース配列RGTRCYCTA(配列番号2)、
修飾HD-51-9:Ac-atcycrtGr-NH2(配列番号5)、
HD-51-13、ATCYCRTGRCATR(配列番号34)、
HD-51-28、ATCYCRTGRCATRESLSGVCEISGRLYR(配列番号12)、
HD-57-32、TGRCATRESLSGVCEISGRLYRLCCR(配列番号14
HD-510-32、CATRESLSGVCEISGRLYRLCCR(配列番号19、
HD-514-32、ESLSGVCEISGRLYRLCCR(配列番号25
HD-510-27CATRESLSGVCEISGRLY(配列番号28)、または
HD-526-32LYRLCCR(配列番号41)からなる。
RGTRCYCTA(配列番号2)、
Ac-atcycrtGr-NH2(配列番号5)、
LYRLCCR(配列番号41)、
ATCYCRTGRCATR(配列番号34)、
ATCYCRTGRCATRESLSGVCEISGRLYR(配列番号12)、または
TGRCATRESLSGVCEISGRLYRLCCR(配列番号14)からなる。
ATCYCRTGR(配列番号1)、
RGTRCYCTA(配列番号2)、
Ac-atcycrtGr-NH2(配列番号5)、または
LYRLCCR(配列番号41)からなる。
ATCYCRTGR(配列番号1)、
RGTRCYCTA(配列番号2)、または
Ac-atcycrtGr-NH2(配列番号5)をベースとしたものが挙げられる。
HD-51-9:ATCYCRTGR(配列番号1)
HD-51-9rev:RGTRCYCTA(配列番号2)
HD-51-9mod:Ac-atcycrtGr-NH2(配列番号5)
HNP-41-11:VCSCRLVFCRR(配列番号3)
HNP-41-11rev:RRCFVLRCSCV(配列番号4)
HNP-41-11mod:Ac-vcscrlvfcrr-NH2(配列番号6)
ペプチド すべての実験で、酸化ペプチドHD-5およびHD-6(Peptide Institute,Osaka,Japan)を使用した。すべての断片、すなわち、HD-51-9およびHNP-41-11、HD-51-13、HD-51-28、HD-57-32、HD-510-32、HD-514-32、HD-510-27およびHD-526-32(本発明のすべてのペプチド)は、EMC microcollections GmbH(Tubingen,Germany)によって合成された。すべてのペプチドを同様の濃度の0.01%酢酸(HAc)に溶解した。
LC/MSを使用したHD-5およびHD-6の断片のスクリーニング。
走査型電子顕微鏡
透過型電子顕微鏡
放射状拡散アッセイ
濁度ブロスアッセイ
細胞毒性アッセイ
溶血アッセイ
In vivoマイクロバイオータ分析
統計分析
ソフトウェア
結果
十二指腸粘液インキュベーション後のin silico(通常の文字)およびex vivoの現実(太字)では、トリプシンまたはキモトリプシン、あるいはその両方を組み合わせたパネート細胞HD-5およびHD-6の消化で、5回まで切断の失敗および500Daを超える断片。ExPASy PeptideMassモジュールを使用した様々な配列の決定。ヒトペプチドをヒト十二指腸粘液とインキュベートした後、質量分析により同定できる断片は太字で示す。表の最初の行は、2つの全長ペプチドを示しており、これらも同定できる。
HD-5断片は、放射状拡散アッセイにおいて抗菌活性がある
HD-5断片および抗生物質耐性菌に対する最小阻害濃度
病原性細菌に対するHD-5断片のMIC(μMおよびμg/ml)。各実験は、少なくとも3回実施した。MICは、12時間のインキュベーション後のすべての実験において、いかなる細菌の成長もない濃度として決定した。
表4:以下の表4は、HD51-9、HD51-9;mod、HNP-41-11、およびHNP-41-11;modの、試験された細菌およびカンジダアルビカンスに対する抗菌活性を示している。12時間後、光学密度により、異なるペプチド濃度を有するA.バウマニ4-MRGN、A.バウマニDSM30007、E.フェシウム475747、E.フェシウムDSM20477、肺炎桿菌3-MRGN、肺炎桿菌DSM301404、緑膿菌4-MRGN、緑膿菌ATCC27853、緑膿菌PAO1、緑膿菌XPAT1、緑膿菌XPAT2、黄色ブドウ球菌USA300、黄色ブドウ球菌ATCC25923、S.エンテリティディス、大腸菌BW25113、Y.エンテロコリチカ、およびC.アルビカンス525Lの最小阻害濃度(MIC)を決定した。3つの独立した実験の結果を示す:
大腸菌BW25113および黄色ブドウ球菌SA113の変異体における細胞壁標的の同定
異なる細菌に対するHD51-9およびHD51-9-二量体の抗菌活性の特性評価
トリプシン消化後の新規HNP-4断片の同定
HNP-41-11の抗菌効果
まとめ
参考文献
1. Lehrer, R. I. & Lu, W. a-Defensins in human innate immunity. lmmunol. Rev. 245, 84-112 (2012).
2. Ericksen, B., Wu, Z., Lu, W. & Lehrer, R. I. Antibacterial Activity and Specificity of the Six Human a-Defensins. Antimicrob. Agents Chemother. 49, 269-275 (2005).
3. Schroeder, B. 0. et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human 13‐defensin 1. Nature 469, 419‐423 (2011).
4. Chu, H. et al. Human a‐defensin 6 promotes mucosal innate immunity through self‐assembled peptide nanonets. Science 337, 477‐481 (2012).
5. Schroeder, B. 0., Stange, E. F. & Wehkamp, J. Waking the wimp: redox‐modulation activates human beta‐defensin 1. Gut Microbes 2, 262‐266 (2011).
6. Wendler, J. et al. Bacterial periplasmic oxido-reductases are essential for the activity of oxidized human antimicrobial 13-defensin 1. Infect. lmmun. IAl.00875-17 (2018) doi:10.1128/IAl.00875-17.
7. Stawikowski, M. & Fields, G. B. Introduction to peptide synthesis. Curr Protoc Protein Sci Chapter 18, Unit 18.1 (2012).
8. Davis, L. Basic Methods in Molecular Biology. (Elsevier, 2012).
9. Sambrook, J., Fritsch, E. F. & Maniatis, T. Molecular cloning: a laboratory manual.
Molecular cloning: a laboratory manual. (1989).
10. Rowe, R. C., Sheskey, P. J., Cook, W. G. & Fenton, M. E. Handbook of Pharmaceutical Excipients. (Pharmaceutical Press, 2012).
11.Schroeder, B. 0. et al.Reduction of disulphide bonds unmasks potent antimicrobial activity of human 13-defensin 1.Nature 469, 419-423 (2011).
12. Lehrer, R. I., Rosenman, M., Harwig, S. S., Jackson, R. & Eisenhauer, P. Ultrasensitive assays for endogenous antimicrobial polypeptides. J. lmmunol. Methods 137, 167-173 (1991).
13. Oddo, A. & Hansen, P. R. Hemolytic Activity of Antimicrobial Peptides. Methods Mol. Biol. 1548, 427--435 (2017).
14. Callahan, B. J. et al. DADA2: High-resolution sample inference from lllumina amplicon data. Nat. Methods 13, 581-583 (2016).
15. McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS One 8, (2013).
16. Paulson, J. N., Stine, 0. C., Bravo, H. C. & Pop, M. Differential abundance analysis for microbial marker-gene surveys. Nature Methods 10, 1200-1202 (2013).
17. Oksanen, J. et al. vegan: Community Ecology Package. (2018).
18. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) I Gomez-Rubio I Journal of Statistical Software. doi:10.18637/jss.v077.b02.
19. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mo/ Syst Biol 2, 2006.0008 (2006).
20. Weidenmaier, C. et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model ofendocarditis. J. Infect. Dis.191, 1771-1777 (2005).
21. Peschel, A. & Collins, L. V. Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin. Peptides 22, 1651-1659 (2001).
22. Wanner, S. et al. Wall teichoic acids mediate increased virulence in Staphylococcus aureus. Nat Microbiol 2, 16257 (2017).
23. Rajabi, M. et al. The conserved salt bridge in human alpha-defensin 5 is required for its precursor processing and proteolytic stability. J. Biol. Chem. 283, 21509- 21518 (2008).
24.Rajabi, M. et al. Functional determinants of human enteric a-defensin HOS: crucial role for hydrophobicity at dimer interface. J. Biol.Chem.287, 21615-21627 (2012).
25. Szyk, A. et al. Crystal structures of human alpha-defensins HNP4, HOS, and HD6.
Protein Sci. 15, 2749-2760 (2006).
26. Wanniarachchi, Y. A., Kaczmarek, P., Wan, A. & Nolan, E. M. Human Defensin 5 Disulfide Array Mutants: Disulfide Bond Deletion Attenuates Antibacterial Activity Against Staphylococcus aureus. Biochemistry 50, 8005-8017 (2011).
27. Hong, S. Y., Oh, J. E. & Lee, K. H. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem. Pharmacol. 58, 1775-1780 (1999).
28. Brinckerhoff, L. H. et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J.Cancer83, 326-334 (1999).
Claims (17)
- 抗菌活性を有するペプチドであって、
配列
ATCYCRTGR(配列番号1)、
RGTRCYCTA(配列番号2)、
Ac-atcycrtGr-NH2(配列番号5)、
VCSCRLVFCRR(配列番号3)、
RRCFVLRCSCV(配列番号4)、
Ac-vcscrlvfcrr-NH 2 (配列番号6)、
LYRLCCR(配列番号41)、
ATCYCRTGRCATR(配列番号34)、
ATCYCRTGRCATRESLSGVCEISGRLYR(配列番号12)、
TGRCATRESLSGVCEISGRLYRLCCR(配列番号14)、
CATRESLSGVCEISGRLYRLCCR(配列番号19)、
ESLSGVCEISGRLYRLCCR(配列番号25)、または
CATRESLSGVCEISGRLY(配列番号28)からなるペプチド。 - 配列
ATCYCRTGR(配列番号1)、
RGTRCYCTA(配列番号2)、
Ac-atcycrtGr-NH2(配列番号5)、
LYRLCCR(配列番号41)、
ATCYCRTGRCATR(配列番号34)、
ATCYCRTGRCATRESLSGVCEISGRLYR(配列番号12)、または
TGRCATRESLSGVCEISGRLYRLCCR(配列番号14)からなる、請求項1に記載のペプチド。 - 配列
ATCYCRTGR(配列番号1)、
RGTRCYCTA(配列番号2)、または
Ac-atcycrtGr-NH2(配列番号5)からなる、請求項1に記載のペプチド。 - 配列
ATCYCRTGR(配列番号1)、または
RGTRCYCTA(配列番号2)からなる、請求項1に記載のペプチド。 - 配列
VCSCRLVFCRR(配列番号3)、
RRCFVLRCSCV(配列番号4)、または
Ac-vcscrlvfcrr-NH 2 (配列番号6)からなる、請求項1に記載のペプチド。 - 前記ペプチドが、ジスルフィド結合を介して連結されたホモ二量体である、請求項1~5のいずれか一項に記載のペプチド。
- アセチル-、ホルミル-、ピログルタミル-、脂肪酸-、尿素-、カルバメート-、およびアルキルアミンから選択されるN末端修飾を含む、請求項1~6のいずれか一項に記載のペプチド。
- -アミド、-酸、-N-アルキル-アミド、-アルデヒド、-エステル、-p-ニトロアニリド、および-7-アミノ-4-メチルクマリンからなる群のうちの1つから選択されるC末端修飾を含む、請求項1~7のいずれか一項に記載のペプチド。
- 前記ペプチドが、D-アミノ酸および/もしくはL-アミノ酸からなるか、またはD-アミノ酸および/もしくはL-アミノ酸を含む、請求項1~8のいずれか一項に記載のペプチド。
- 前記ペプチドが、N末端および/またはC末端修飾を含み、前記修飾が、N末端アセチル修飾および/またはC末端アミド修飾である、請求項1~9のいずれか一項に記載のペプチド。
- マイクロバイオームの調節に使用するための、または皮膚、口、腸、肺、目、耳、膣もしくはCNSの状態もしくは異常に関連する他の疾患の治療および/もしくは予防に使用するための、請求項1~10のいずれか一項に記載のペプチド。
- 前記疾患が、皮膚の疾患、口の疾患、炎症性腸疾患、代謝性疾患、肺疾患、目の疾患、耳の疾患、膣の疾患、敗血症、および精神疾患から選択される、請求項11に記載の使用のためのペプチド。
- 前記疾患が、クローン病、潰瘍性大腸炎、セリアック病、壊死性腸炎、過敏性腸症候群、海外旅行者下痢症、消化器癌、糖尿病および前糖尿病、肥満、NAFLD、NASH、脂質異常症、ぜん息、COPD、アトピー性皮膚炎、酒さ様皮膚炎、脂漏性皮膚炎、湿疹、癰、ブドウ球菌感染症、カンジダ症、蜂巣炎、伝染性膿痂疹、尋常性ざ瘡、毛巣洞、皮膚リンパ腫、水虫、白癬、伝染性軟属腫、歯周炎、虫歯、ドライアイ、シェーグレン病、結膜炎、眼瞼炎、麦粒腫、霰粒腫、眼窩周囲蜂巣炎、涙嚢炎、眼内炎、ブドウ膜炎、虹彩炎、乳様突起炎、前庭神経炎、水疱性鼓膜炎、顆粒性脊髄炎、外耳炎、中耳炎、細菌性膣炎、トリコモナス膣炎、カンジダ、非感染性膣炎、炎症性膣炎、敗血症、統合失調症、パーキンソニズム、双極性障害、うつ病、ならびに自閉症から選択される、請求項12に記載の使用のためのペプチド。
- 前記ペプチドが、抗菌剤として使用される、請求項11~13のいずれか一項に記載の使用のためのペプチド。
- 前記ペプチドが経口的に、非経口的に、または局所的に投与される、請求項11~14のいずれか一項に記載の使用のためのペプチド。
- 請求項1~10のいずれか一項に記載のペプチドおよび薬学的に許容される担体を含む医薬組成物。
- 口、目、耳、皮膚、または膣への局所投与用に配合されている、請求項16に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019100230.3 | 2019-01-07 | ||
DE102019100230 | 2019-01-07 | ||
DE102019108626 | 2019-04-02 | ||
DE102019108626.4 | 2019-04-02 | ||
PCT/EP2020/050186 WO2020144166A1 (en) | 2019-01-07 | 2020-01-07 | Defensin fragments for use in therapy or prophylaxis |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022517764A JP2022517764A (ja) | 2022-03-10 |
JPWO2020144166A5 JPWO2020144166A5 (ja) | 2023-01-20 |
JP7479381B2 true JP7479381B2 (ja) | 2024-05-08 |
Family
ID=69167795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021539592A Active JP7479381B2 (ja) | 2019-01-07 | 2020-01-07 | 治療または予防に使用するためのディフェンシン断片 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220064217A1 (ja) |
EP (1) | EP3908305A1 (ja) |
JP (1) | JP7479381B2 (ja) |
KR (1) | KR20210126585A (ja) |
CN (1) | CN113453701A (ja) |
AU (1) | AU2020207527A1 (ja) |
BR (1) | BR112021013434A2 (ja) |
CA (1) | CA3125689A1 (ja) |
MX (1) | MX2021008249A (ja) |
SG (1) | SG11202107310RA (ja) |
WO (1) | WO2020144166A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114456232B (zh) * | 2021-11-09 | 2023-09-29 | 中国科学院动物研究所 | 抑制饮食性肥胖的药物及其所用多肽 |
KR20230122899A (ko) * | 2022-02-15 | 2023-08-22 | 주식회사 나이벡 | 항균, 항염증 또는 조직재생능을 구비하는 펩타이드 및 이의 용도 |
CN117304297B (zh) * | 2023-10-18 | 2024-05-31 | 河南大学 | 一种重组人α-防御素5及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007081486A2 (en) | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
WO2017129195A1 (en) | 2016-01-26 | 2017-08-03 | Defensin Therapeutics Aps | Methods for modulating intestinal microbiota |
WO2017186250A1 (en) | 2016-04-29 | 2017-11-02 | Defensin Therapeutics Aps | Treatment of liver, biliary tract and pancreatic disorders |
WO2018108971A2 (en) | 2016-12-13 | 2018-06-21 | Defensin Therapeutics Aps | Methods for treating inflammatory conditions of the lungs |
-
2020
- 2020-01-07 KR KR1020217025114A patent/KR20210126585A/ko unknown
- 2020-01-07 JP JP2021539592A patent/JP7479381B2/ja active Active
- 2020-01-07 WO PCT/EP2020/050186 patent/WO2020144166A1/en active Application Filing
- 2020-01-07 MX MX2021008249A patent/MX2021008249A/es unknown
- 2020-01-07 CN CN202080015217.3A patent/CN113453701A/zh active Pending
- 2020-01-07 CA CA3125689A patent/CA3125689A1/en active Pending
- 2020-01-07 EP EP20700766.7A patent/EP3908305A1/en active Pending
- 2020-01-07 US US17/420,155 patent/US20220064217A1/en active Pending
- 2020-01-07 SG SG11202107310RA patent/SG11202107310RA/en unknown
- 2020-01-07 AU AU2020207527A patent/AU2020207527A1/en active Pending
- 2020-01-07 BR BR112021013434-4A patent/BR112021013434A2/pt not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007081486A2 (en) | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
WO2017129195A1 (en) | 2016-01-26 | 2017-08-03 | Defensin Therapeutics Aps | Methods for modulating intestinal microbiota |
WO2017186250A1 (en) | 2016-04-29 | 2017-11-02 | Defensin Therapeutics Aps | Treatment of liver, biliary tract and pancreatic disorders |
WO2018108971A2 (en) | 2016-12-13 | 2018-06-21 | Defensin Therapeutics Aps | Methods for treating inflammatory conditions of the lungs |
Also Published As
Publication number | Publication date |
---|---|
KR20210126585A (ko) | 2021-10-20 |
EP3908305A1 (en) | 2021-11-17 |
US20220064217A1 (en) | 2022-03-03 |
WO2020144166A1 (en) | 2020-07-16 |
BR112021013434A2 (pt) | 2021-10-19 |
MX2021008249A (es) | 2021-10-13 |
CA3125689A1 (en) | 2020-07-16 |
AU2020207527A1 (en) | 2021-08-19 |
CN113453701A (zh) | 2021-09-28 |
JP2022517764A (ja) | 2022-03-10 |
SG11202107310RA (en) | 2021-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10980848B2 (en) | Antimicrobial therapy | |
JP7479381B2 (ja) | 治療または予防に使用するためのディフェンシン断片 | |
US20170073371A1 (en) | Antimicrobial peptides | |
Pangsomboon et al. | Antibacterial activity of a bacteriocin from Lactobacillus paracasei HL32 against Porphyromonas gingivalis | |
US10781236B2 (en) | Bacteriocin composition and method | |
Shekh et al. | Biochemical characterization of an anti-Candida factor produced by Enterococcus faecalis | |
An et al. | Colorectal cancer therapy using a Pediococcus pentosaceus SL4 drug delivery system secreting lactic acid bacteria-derived protein p8 | |
WO2010148079A9 (en) | Antimicrobial and antibiofilm activity of cathelicidins | |
JP2006519217A (ja) | 抗菌剤 | |
Rani et al. | Role of bacteriocins in modulation of microbiome in human diseases | |
Rani et al. | Health benefits of bacteriocins produced by probiotic lactic acid bacteria | |
Hashim | Investigating the potential of biosurfactants in the control of tooth infections | |
Coppenhagen-Glazer et al. | LL-37 Opsonizes and Inhibits Biofilm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210917 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230106 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240326 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240326 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240423 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7479381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |